Compare $LIMN vs $PMCB | Chartloom

Compare

$LIMN vs $PMCB

Liminatus Pharma Inc · PharmaCyte Biotech Inc

LIMN

Liminatus Pharma Inc

PMCB

PharmaCyte Biotech Inc

Compare $LIMN vs $PMCB

Comparing Liminatus Pharma Inc and PharmaCyte Biotech Inc

LIMNLiminatus Pharma Inc

PMCBPharmaCyte Biotech Inc

LIMNLiminatus Pharma Inc

Market cap

$253M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-88.3%

52W performance

-95.3%

FCF yield

-1.6%

PMCBPharmaCyte Biotech Inc

Market cap

$4M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-45.2%

52W performance

-60.4%

FCF yield

-90.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LIMN

PMCB

Detailed metrics comparison

LIMN

Liminatus Pharma Inc

PMCB

PharmaCyte Biotech Inc

Market Cap

LIMN$253M

PMCB$4M

Enterprise Value

LIMN$251M

PMCB$-13M

Price

LIMN$3.76

PMCB$0.40

P/E Ratio

LIMNN/A

PMCBN/A

P/S Ratio

LIMN0.00x

PMCB107.65x

EV/Sales

LIMN0.00x

PMCB-336.93x

EV/EBITDA

LIMN0.00x

PMCB0.00x

P/B Ratio

LIMN17.43x

PMCB0.14x

P/FCF Ratio

LIMNN/A

PMCBN/A

EV/FCF

LIMN-62.96x

PMCB3.40x

PEG Ratio

LIMNN/A

PMCBN/A

Forward P/E (NTM)

LIMNN/A

PMCBN/A

Forward P/S (NTM)

LIMNN/A

PMCBN/A

Revenue (TTM)

LIMN$0

PMCB$0

Revenue Growth (YoY)

LIMNN/A

PMCBN/A

Forward Rev Growth

LIMN0.0%

PMCB0.0%

Gross Margin (TTM)

LIMN0.0%

PMCB81.7%

Operating Margin (TTM)

LIMN0.0%

PMCB0.0%

EBITDA Margin (TTM)

LIMN0.0%

PMCB0.0%

Net Margin (TTM)

LIMN0.0%

PMCB0.0%

FCF Margin (TTM)

LIMNN/A

PMCBN/A

Net Income (TTM)

LIMN$-13M

PMCB$-21M

FCF (TTM)

LIMN$-4M

PMCB$-4M

EPS (TTM)

LIMN-$12.94

PMCB-$1.92

ROE (TTM)

LIMN0.0%

PMCB-4588.0%

ROA (TTM)

LIMN-62234.0%

PMCB-3307.0%

ROIC (TTM)

LIMN0.0%

PMCB-4588.0%

Cash

LIMN$3M

PMCB$18M

Debt

LIMN$1M

PMCB$0

Net Cash/Debt

LIMN$2M

PMCB$18M

Current Ratio (TTM)

LIMN1.12x

PMCB40.30x

Quick Ratio (TTM)

LIMN0.99x

PMCB40.25x

Debt/Equity (TTM)

LIMN4.80x

PMCB0.00x

Debt/Assets (TTM)

LIMN0.0%

PMCB0.0%

Interest Coverage (TTM)

LIMNN/A

PMCBN/A

Net Debt/EBITDA (TTM)

LIMN0.00x

PMCB0.00x

Beta

LIMN0.75

PMCB0.74

52W Performance

LIMN-95.3%

PMCB-60.4%

YTD Performance

LIMN-88.3%

PMCB-45.2%

% from 52W High

LIMN-97.3%

PMCB-73.2%

% from 52W Low

LIMN14.3%

PMCB21.1%

Asset Turnover (TTM)

LIMN0.00x

PMCB0.02x

FCF Yield (TTM)

LIMN-1.6%

PMCB-90.7%

Earnings Yield (TTM)

LIMN-5.0%

PMCB-475.0%

Dividend Yield (TTM)

LIMNN/A

PMCBN/A

Rule of 40

LIMN0.0

PMCB0.0

EV/GP/RG

LIMNN/A

PMCBN/A

Ticker research

View LIMN research View PMCB research

Metric	LIMN Liminatus Pharma Inc	PMCB PharmaCyte Biotech Inc
Market & Valuation
Market Cap	$253M	$4M
Enterprise Value	$251M	$-13M
Price	$3.76	$0.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	107.65x
EV/Sales	0.00x	-336.93x
EV/EBITDA	0.00x	0.00x
P/B Ratio	17.43x	0.14x
P/FCF Ratio	N/A	N/A
EV/FCF	-62.96x	3.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	81.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-13M	$-21M
FCF (TTM)	$-4M	$-4M
EPS (TTM)	-$12.94	-$1.92
ROE (TTM)	0.0%	-4588.0%
ROA (TTM)	-62234.0%	-3307.0%
ROIC (TTM)	0.0%	-4588.0%
Financial Health
Cash	$3M	$18M
Debt	$1M	$0
Net Cash/Debt	$2M	$18M
Current Ratio (TTM)	1.12x	40.30x
Quick Ratio (TTM)	0.99x	40.25x
Debt/Equity (TTM)	4.80x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.75	0.74
52W Performance	-95.3%	-60.4%
YTD Performance	-88.3%	-45.2%
% from 52W High	-97.3%	-73.2%
% from 52W Low	14.3%	21.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-1.6%	-90.7%
Earnings Yield (TTM)	-5.0%	-475.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LIMN research	View PMCB research

Valuation

P/S Ratio

LIMN

0.00x

PMCB

107.65x

EV/FCF

LIMN

-62.96x

PMCB

3.40x

Growth & revenue

Forward Revenue Growth

LIMN

0.0%

PMCB

0.0%

Profitability & performance

Gross Margin

PMCB

81.7%

LIMN

0.0%

ROE

LIMN

0.0%

PMCB

-4588.0%

FCF Yield %

LIMN

-1.6%

PMCB

-90.7%

52-Week Performance

PMCB

-60.4%

LIMN

-95.3%

Detailed metrics comparison

LIMN

Liminatus Pharma Inc

PMCB

PharmaCyte Biotech Inc

Market Cap

LIMN$253M

PMCB$4M

Enterprise Value

LIMN$251M

PMCB$-13M

Price

LIMN$3.76

PMCB$0.40

P/E Ratio

LIMNN/A

PMCBN/A

P/S Ratio

LIMN0.00x

PMCB107.65x

EV/Sales

LIMN0.00x

PMCB-336.93x

EV/EBITDA

LIMN0.00x

PMCB0.00x

P/B Ratio

LIMN17.43x

PMCB0.14x

P/FCF Ratio

LIMNN/A

PMCBN/A

EV/FCF

LIMN-62.96x

PMCB3.40x

PEG Ratio

LIMNN/A

PMCBN/A

Forward P/E (NTM)

LIMNN/A

PMCBN/A

Forward P/S (NTM)

LIMNN/A

PMCBN/A

Revenue (TTM)

LIMN$0

PMCB$0

Revenue Growth (YoY)

LIMNN/A

PMCBN/A

Forward Rev Growth

LIMN0.0%

PMCB0.0%

Gross Margin (TTM)

LIMN0.0%

PMCB81.7%

Operating Margin (TTM)

LIMN0.0%

PMCB0.0%

EBITDA Margin (TTM)

LIMN0.0%

PMCB0.0%

Net Margin (TTM)

LIMN0.0%

PMCB0.0%

FCF Margin (TTM)

LIMNN/A

PMCBN/A

Net Income (TTM)

LIMN$-13M

PMCB$-21M

FCF (TTM)

LIMN$-4M

PMCB$-4M

EPS (TTM)

LIMN-$12.94

PMCB-$1.92

ROE (TTM)

LIMN0.0%

PMCB-4588.0%

ROA (TTM)

LIMN-62234.0%

PMCB-3307.0%

ROIC (TTM)

LIMN0.0%

PMCB-4588.0%

Cash

LIMN$3M

PMCB$18M

Debt

LIMN$1M

PMCB$0

Net Cash/Debt

LIMN$2M

PMCB$18M

Current Ratio (TTM)

LIMN1.12x

PMCB40.30x

Quick Ratio (TTM)

LIMN0.99x

PMCB40.25x

Debt/Equity (TTM)

LIMN4.80x

PMCB0.00x

Debt/Assets (TTM)

LIMN0.0%

PMCB0.0%

Interest Coverage (TTM)

LIMNN/A

PMCBN/A

Net Debt/EBITDA (TTM)

LIMN0.00x

PMCB0.00x

Beta

LIMN0.75

PMCB0.74

52W Performance

LIMN-95.3%

PMCB-60.4%

YTD Performance

LIMN-88.3%

PMCB-45.2%

% from 52W High

LIMN-97.3%

PMCB-73.2%

% from 52W Low

LIMN14.3%

PMCB21.1%

Asset Turnover (TTM)

LIMN0.00x

PMCB0.02x

FCF Yield (TTM)

LIMN-1.6%

PMCB-90.7%

Earnings Yield (TTM)

LIMN-5.0%

PMCB-475.0%

Dividend Yield (TTM)

LIMNN/A

PMCBN/A

Rule of 40

LIMN0.0

PMCB0.0

EV/GP/RG

LIMNN/A

PMCBN/A

Ticker research

View LIMN research View PMCB research

Metric	LIMN Liminatus Pharma Inc	PMCB PharmaCyte Biotech Inc
Market & Valuation
Market Cap	$253M	$4M
Enterprise Value	$251M	$-13M
Price	$3.76	$0.40
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	107.65x
EV/Sales	0.00x	-336.93x
EV/EBITDA	0.00x	0.00x
P/B Ratio	17.43x	0.14x
P/FCF Ratio	N/A	N/A
EV/FCF	-62.96x	3.40x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	0.0%	0.0%
Profitability
Gross Margin (TTM)	0.0%	81.7%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-13M	$-21M
FCF (TTM)	$-4M	$-4M
EPS (TTM)	-$12.94	-$1.92
ROE (TTM)	0.0%	-4588.0%
ROA (TTM)	-62234.0%	-3307.0%
ROIC (TTM)	0.0%	-4588.0%
Financial Health
Cash	$3M	$18M
Debt	$1M	$0
Net Cash/Debt	$2M	$18M
Current Ratio (TTM)	1.12x	40.30x
Quick Ratio (TTM)	0.99x	40.25x
Debt/Equity (TTM)	4.80x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.75	0.74
52W Performance	-95.3%	-60.4%
YTD Performance	-88.3%	-45.2%
% from 52W High	-97.3%	-73.2%
% from 52W Low	14.3%	21.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-1.6%	-90.7%
Earnings Yield (TTM)	-5.0%	-475.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View LIMN research	View PMCB research